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The third  component of complement (C) ~ has a  central role in the activation 
of both the classical and alternative pathways. C3 also has a  variety of different 
functions  that  are  expressed  either  after  C3  activation  or  during  the  normal 
breakdown  of the  molecule.  These  functions  of C3  are  dependent  upon  the 
exposure within  C3 of binding sites for other serum proteins or for membrane 
C3  receptors.  None  of these  binding  sites  is available in  native  C3  (1,  2),  and 
each  type of binding site is exposed only during  C3  activation and  subsequent 
fragmentation.  The  structure  and  function  of the  different  C3  fragments and 
the  mechanism of their  generation  has been a  subject of intense  research after 
initial reports that inactivated C3b (iC3b) expressed functions that were distinct 
from those of C3b (3, 4).  Recent studies have now demonstrated that factor I is 
the primary enzyme responsible for the  normal physiologic breakdown  of C3b 
(5-7).  The key to defining the pathway of I cleavage of C3b was the demonstra- 
tion that two different cofactors are required for l  cleavage of C3b and iC3b (6, 
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7). H  is the cofactor for I cleavage of fluid-phase C3b (8, 9), whereas erythrocyte 
(E) membrane CRj  is the cofactor for I  cleavage of fixed iC3b into fixed C3d,g 
and  fluid-phase  C3c  (6,  7).  Even  though  CR1  may also  serve as cofactor for I 
cleavage of fluid C3b (10), CR~ probably can not replace H as the control protein 
of the  alternative  pathway,  as  patients  with  inherited  H  deficiency (11)  have 
unregulated C3 activation resembling patients with I deficiency (12). 
In the present investigation,  the C3  fragments resulting from activation and 
breakdown  by I  and  trypsin  were examined for binding sites for six  different 
C3-1igands: factors B and H, CRy, CRy, CR3, and conglutinin (K). Evidence was 
obtained for at least four distinct binding sites in the C3 fragments for these six 
C3 ligands. 
Materials and Methods 
Buffers.  Assays were performed in either isotonic or low ionic strength buffers con- 
taining  either  divalent  cations,  EDTA,  or  EGTA.  Isotonic  buffers  included:  Hanks 
balanced salt solution (HBSS) containing  1% BSA  and either 0.6 mM calcium and 0.9 
mM magnesium or 20 mM EDTA; and gelatin veronal buffer (GVB) containing either 
0.15 mM calcium and 0.5 mM magnesium or 0.15 mM nickel. The low ionic strength 
buffers used  were: dextrose gelatin veronal buffer (DGVB, 4  mS at  22°C) containing 
either 0.15 mM calcium and 0.5 mM magnesium or 0.15 mM nickel; 3.5 mM veronal 
buffer containing 10 mM sodium chloride, 1% BSA, 3.5% dextrose, 0.2% sodium azide, 
and 2 mM each of calcium chloride and magnesium chloride (BDVA, pH 7.2 and 4 mS 
at 22°C); and calcium-magnesium-free BDVA with 20 mM EDTA (BDVEA, pH 7.2 and 
6 mS at 22°C). 
Leukocvtes and  Ervthrocvtes (E).  Blood from  normal  volunteers was  drawn  into acid 
citrate dextrose anticoagulant. After sedimentation of erythrocytes with dextran, mono- 
nuclear cells and neutrophils were separated by centrifugation on a two-step (d =  1.08 
and 1.105) density gradient of FicolI-Hypaque as previously described (I 3). Erythrocytes, 
taken from the dextran-sedimented fraction, and Raji lymphoblasts, cultured in RPMI 
1640  with  10%  heat-inactivated  fetal  calf serum,  were  each  washed  three  times  in 
phosphate-buffered saline (PBS) before assay of C receptors. Each cell type was suspended 
at 4 ×  106/ml in EDTA/HBSS/BSA, and maintained at room temperature until exam- 
ined for C receptors. Soybean trypsin inhibitor (Sigma Chemical Co, St Louis, MO) at 1 
mg/ml was added to all neutrophil preparations to inhibit elastase activity (13).  Where 
indicated, portions of each cell type were resuspended before C  receptor assay  at 4  × 
106/ml in either HBSS/BSA, BDVA, or BDVEA. 
C  Components, To,psi,,  and  Serum  Reagents.  C3,  B,  D,  H,  and  I  were  isolated  as 
previously described (6, 14). Trypsin was obtained from Sigma Chemical Co. Isotonic and 
low  ionic strength  (4  mS at  22°C)  heat-inactivated serum  reagents  were  prepared as 
before (6). 
Purificatio,  of C3  Fragments.  C3b,  iC3b,  C3c,  C3d,g,  and  C3d  were  prepared  on 
Activated Thiol Sepharose (ATS, Pharmacia Fine Chemicals, Piscataway, NJ) and eluted 
with  10 mM cysteine, pH 7.0 as previously described (6). ATS-iC3b was prepared by H 
and I  treatment of ATS-C3b in  isotonic salt buffer, and contained no trace of C3b or 
C3d,g on SDS-PAGE. ATS-C3d,g, prepared by H  and I treatment of ATS-C3b at low 
ionic strength  (1.4  mS),  contained  ~10%  iC3b (6).  To remove iC3b from one C3d,g 
preparation, the C3d,g was absorbed with agarose coupled to monoclonal anti-C3c (clone 
4) (15).  Two C3c preparations were used, one generated by elastase treatment of ATS- 
C3b, and the other by H and I treatment of ATS-C3b in 1.4 mS buffer (6). 
Preparation  of C3-Coated Fluorescent Microspheres.  Fluorescent  microspheres  (Covas- 
pheres, Covalent Technology Corp, Ann Arbor, MI) were coated with iC3b, C3d,g, and 
C3c as previously described (13). Control BSA-coated microspheres were always prepared 
in parallel. 
Formatio,  of Sheep Eo,throcvte-C3 Complexes (EC3) and Quantitation of The Different Fixed 336  LOCATION OF  DIFFERENT  BINDING SITES  IN  C3  FRAGMENTS 
C3 Fragme~ts With veSI-Labeled  Monoclonal Antibodies Specific For C3c, C3g, and C3d.  EC3b 
was prepared  by two  cycles of C3  addition,  first  with  trypsin,  and  then  with  a  bound 
nickel-stabilized C3-convertase formed with B and D (6). EC3bi was prepared by treatment 
of EC3b for  15  min at  37°C with  isotonic heat-inactivated  serum,  1.0 ml per  1 x  109 
EC3b (6).  EC3d,g was prepared  by treatment  of EC3b for 60  min at  37°C with  4  mS 
heat-inactivated serum,  1.0 ml per  1 x  109 EC3b (6).  EC3d was prepared from EC3bi or 
EC3d,g by incubation for 30 min at 37°C at  1 x  109/ml in PBS containing 10 ~g/ml of 
trypsin (6).  EC3 were prepared with different amounts of C3 and the amount and type of 
bound  C3  fragments  were  quantitated  by assay  for  uptake  of v"~I-labeled monoclonal 
antibodies specific for C3c, C3g, and C3d (6).  One anti-C3c IgG (kindly donated by Dr. 
Charles Parker,  Duke University, Durham, NC) was purified from ascites fluid obtained 
from Bethesda  Research  Laboratories (Gaithersburg,  MD) by column chromatography 
on DEAE cellulose. A  second anti-C3c IgG, clone 4, (15) was isolated from ascites fluid 
(made pH 5 with acetic acid) by precipitation with 5% caprylic acid (Sigma Chemical Co.) 
followed by precipitation of the caprylic acid supernatant with 50% saturated ammonium 
sulphate. Clone 9 anti-C3g (15) and clone 3 anti-C3d (15) were isolated in a similar way. 
Each anti-C3  was iodinated  to a  specific activity of 0.7-2.5  uCi/t~g IgG using Iodogen 
(Pierce Chemical Co., Rockford, IL) (16). 
In the  first  step of C3 addition  with  trypsin forming EC3bn,  the amount of C3 and 
trypsin (6) were adjusted for maximum C3b fixation without further trypsin cleavage of 
the bound C3b. Any cleavage of fixed C3b on the EC3bT was detected with ~25I-anti-C3g, 
that  bound  only to fixed  iC3b and  to fixed  C3d,g and  not  to fixed  C3b (6,  17).  The 
analysis of a typical preparation of EC3 is given in Table I. Conversion of EC3b to EC3bi 
o  12~  required 5 min at 37  C, and was determined to be complete when the uptake of  I-anti- 
125  125  C3g was equivalent to the uptake of  '  I-anti-C3c and  '" I-anti-C3d. Incomplete conversion 
to iC3b was indicated if the uptake of ~25I-anti-C3g  was less than the uptake of ~25I-anti- 
C3c and  ~25I-anti-C3d,  whereas  over-cleavage of iC3b to C3d,g was indicated when the 
uptake of ~251-anti-C3c was less than the uptake of J2'~I-anti-C3g and ~25I-anti-C3d.  These 
conclusions derived  with  monoclonal antibodies were initially confirmed by SDS-PAGE 
and autoradiography of EC3 prepared with J25I-labeled C3 (6).  EC3d,g always contained 
5% factor I-resistant C3b and iC3b, as indicated both by uptake of v~SI-anti-C3c (Table I) 
and by SDS-PAGE autoradiography (6).  EC3d contained  ~3%  contaminating C3b, but 
no detectable iC3b. This was indicated both by the uptake of ~25I-anti-C3c  in the absence 
of significant  uptake  of J25I-anti-C3g (Table  I) and  by SDS-PAGE autoradiography  of 
EC3d prepared with v25I-labeled  C3. (6). 
Anti-CRy, Anti-H,  and Anti-Mac-1.  Rabbits were immunized with purified CRj (10,  18) 
or H  (14), and the F(ab').~ fragments of the IgG antibodies were isolated (18). Analysis of 
TABLE  I 
Detection A~ld Qua~ttitatiolt Of Different C3 Fragments on EC3 With 
12r'l-Labeled Monoclo~ml Antibodies Specific  for C3c, C3g, and C3d 
EC3 type 
Molecules 1251-anti-C3 bound per EC3 
Anti-C3c  Anti-C3g  Anti-C3d 
EC3bT*  5.7 x  103  1.3 x  102  5.4 ×  l0  s 
EC3b*  3.3 x  104  2.1 x  10  '~  3.5 x  104 
EC3bi  §  2.8 x  104  2.7 x  104  2.8 ×  104 
EC3d,g~  8.1 ×  102  2.5 x  104  2.6 X 104 
EC3d  ~  7.1 X 10  ~  2.4 ×  10 j  2.3 X 104 
* EC3b~-:  prepared by trypsin activation  of 2 mg of C3 in the presence of 
1 x  10~° sheep E. 
* EC3b: prepared by addition  of 100/~g C3 per 1 X 109 EC3bT,Bb,Ni  ++ 
(see Materials and Methods). 
§ EC3bi, EC3d,g and EC3d were prepared from EC3b (see Materials and 
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the anti-H by immunodiffusion and immunoelectrophoresis demonstrated a single precip- 
itin line of identity between purified H and human serum. In addition, the anti-H did not 
contain anti-C3 detectable by assay for agglutination of EC3b nor anti-CR~  detectable by 
assay for inhibition of human E rosette formation with EC3b. Tissue culture supernatant 
containing 100 #g/ml of anti-Mac-1 antibody (19) was kindly provided by Dr. T. Springer 
(Sidney Farber Cancer Institute, Boston, MA). 
Soluble C3d-Sheep E Membrane Complexes (C3d-OR).  The membranes of 6 ×  10 "q EC3d 
bearing 7.1  ×  104 C3d per E, and only 3.6  ×  103 C3b and 7.1  ×  101  iC3b per E, were 
produced by lysis of the EC3d in 5 mM phosphate buffer, and then were solubilized with 
0.25%  Nonidet  P40  as described by Fearon  et al.  (20)  for C3b-OR.  After removal of 
detergent with Bio-Beads SM-2 (Bio-Rad Laboratories, Richmond, CA) the C3d-OR were 
concentrated to 1.2 ml, dialyzed against BDVA, and stored at 4°C. 
Assal's For Factor B Bindil~g To C3.  Purified B was examined for binding to C3b and 
iC3b tl~at were covalently attached to ATS or sheep E. 1-cm x  15-cm columns containing 
either ATS-C3b or ATS-iC3b (3.4 mg C3b or iC3b/ml ATS) (6) were equilibrated with 
3.5  mM veronal buffer, pH 7.2 containing either 0.5  mM magnesium chloride or 0.15 
mM nickelous chloride (-~ 1 mS at 22°C).  Binding of 5.0 mg of B passed through these 
two columns was assessed by measuring B hemolytic activity in 1-ml fractions eluted at 20 
ml/h at 4°C. The B contained  10% contamination with hemopexin that was monitored 
in column fractions by Ouchterlony assay. B titrations were performed with EC3b (1  x 
10S/ml) in DGVB containing 0.15 mM nickelous chloride, (DGVB-Ni). 25/zl dilutions of 
B in  DGVB-Ni were mixed with 25 ul of D (200 ng/ml) and 25/zl of EC3b in V-bottom 
microtiter plates and incubated with agitation for 3 min at 37°C.  Next, 25/~1 of 80 mM 
EDTA, pH 7.2 and 25 ~1 of guinea pig C diluted 1:15 in 40 mM EDTA-GVB were added 
in succession, and incubation continued with agitation for 45 rain at 37°C.  To assess  B 
binding to EC3bi, this assay was carried out with EC3bi instead of with EC3b. 
Assay for H Binding to EC3b and EC3bi.  H  (2 mg) was labeled with 0.5 mCi 12~I using 
Iodogen (16), and had a specific activity of 0.05 t~Ci/gg. Increasing volumes of the [125I]- 
H (750 ug/ml in PBS) were added to duplicate 10-mm ×  75-mm plastic tubes containing 
1 ×  l0 s sheep E, EC3b, or EC3bi in either GVB or DGVB to give a total volume of 200 
~zl, After incubation for 30 min at 30°C,  100 ~1 (5 x  107 cells) was layered onto 1.0 ml of 
a 7:3 mixture of n-butyl phthalate and dinonyl phthalate (Sigma Chemical Co.) in a  1.5- 
ml tube and centrifuged for 45 s at 8,000 g. The supernatant containing the free [I~sI]-H 
was then aspirated and the amount of EC3-bound [12"~I]-H was determined by cutting off 
the bottom of the tube just above the pellet and counting it in a  gamma counter (23). 
The  nonspecific uptake of [r"~I]-H  by E  was subtracted  from the  total  [12"~I]-H uptake 
observed with EC3 to determine the specific uptake of ['2'~I]-H. The concentration of free 
unbound [v~sI]-H was calculated by subtraction of the specifically bound [125I]-H concen- 
tration from the total [v~~I]-H concentration in the assay mixture. The H-binding affinity 
was determined from the slopes of Scatchard plots derived by plotting the ratio of bound/ 
free H concentrations versus the concentration of bound H (24). 
Assay  of A~ti-H  and  anti-CR~ for  Inhibition  of 4  mS  Serum-mediated  C3c  Release from 
EC3bi.  1.0-ml volumes of low ionic strength heat-inactivated serum (6) were mixed with 
250/zl  of either PBS, F(ab')e anti-H (18.1  mg/ml), F(ab'),~ anti-CR1  (1.65  mg/m[), or a 
mixture containing  F(ab')z anti-H and  F(ab')2 anti-CR1  (18.1  mg/ml and  1.65  mg/ml 
respectively). The amount of anti-CR~  used was shown to be sufficient to block the EC3b 
rosetting ability of 4 ×  109 human E. After 1 h at room temperature, the antibody- and 
PBS-treated  samples  were  centrifuged  at  10,000  g  for  30  min  to  remove  immune 
precipitates.  Each of the  H- and/or  CRy-depleted serum  reagents were then added  to 
pellets of 1 x  109 EC3bi (2. I x  104 iC3b per E), and following resuspension of the EC3bi, 
the mixtures were incubated for 2 h at 37 °C. After three washes with BDVEA, the EC3bi 
were analyzed for conversion to EC3d,g by tests for the  uptake of ~SI-labeled anti-C3c 
and anti-C3g (6). To distinguish nonspecific shedding of uncleaved iC3b molecules from 
the EC3bi, an additional  1 ×  10  "° EC3bi were incubated in  1.0  ml of DGVB for 2 h at 
37 °C. I-specific C3c release was determined from this control (6). 
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(13).  The  buffer  used  for  rosette  assays  is  listed  in  Tables  I-V.  With  some  recently 
purchased lots of microspheres, nonspecific binding of BSA-ms was so high that these lots 
of microspheres could not be used for preparation of C3-ms. 
Assays For C Receptor Specificity,.  C receptor specificity was determined by treatment of 
C receptor cells with either anti-C-receptor antibody, C3 fragments, or C3d-OR before 
assay of C-receptors (13).  The F(ab')~-anti-CRl  was 8.2  mg/ml  in PBS and 5 #1 (41  ug) 
was sufficient to inhibit  CR~  activity completely on 4  x  10 ~ monocytes or neutrophils. 
Anti-Mac-1  was used  to inhibit  CRs activity (21).  Monocytes and  neutrophils  (4  x  10  "~) 
were treated with 10 #1 to 20 #1 of anti-Mac-1  tissue culture supernatant and then washed 
once before assay of C receptors. The concentrations of C3 fragments used for inhibition 
are listed in Table II. 50 #1 of C3d-OR was required to produce 50% inhibition of EC3d 
rosette formation with Raji cells, and the same amount of C3d-OR was used in experiments 
with monocytes and neutrophils. 
In experiments that examined the divalent cation requirements  for EC3bi binding to 
CRs and K, the EC3bi and monocytes (anti-CRj-treated)  were first washed with  20 mM 
EDTA/HBSS/BSA and then  washed twice and resuspended  in  HBSS/BSA containing 
either 2 mM calcium chloride, a mixture of 2 mM EGTA and 2 mM magnesium chloride, 
or a mixture of 2 mM calcium chloride and 2 mM magnesium chloride. 
N-acetyl-n-glucosamine  (NADG)  was  purchased  from  BDH  chemicals  Ltd.  (Poole, 
England) and various amounts were added to BDVA. After incubation of both EC3bi and 
monocytes (anti-CRy-treated) in the NADG/BDVA for 15 min at 22°C, the EC3bi were 
mixed with the monocytes and analyzed for rosette formation. 
Put,cation and Assay of K.  K was isolated from bovine serum by EDTA elution from 
yeast cell walls (22).  K  was titrated  in  U-bottom microtiter plates for conglutination of 
EC3bi suspended at  1 x  10~/ml in GVB containing either 2 mM calcium chloride, 2 mM 
each of EGTA and magnesium chloride, or 2 mM each of calcium chloride and magnesium 
chloride. Conglutination  was allowed to develop for 2 h  at 4°C before visual estimation 
of the 50% endpoint. 
Results 
Binding of B to C3b but Not to iC3b.  Previous studies have demonstrated  that 
under physiologic conditions B binds to C3b but not to iC3b, and that binding 
requires magnesium (Mg++).  Because the binding of B to C3b is charge-dependent 
(23) and enhanced  by substitution of nickel  (Ni ++) for Mg  ++ (25),  studies were 
undertaken to determine if a binding site for B could be detected in iC3b using 
a  low  ionic  strength  buffer  containing  Ni ++.  First,  B  was  passed  through  two 
columns containing either ATS-C3b or ATS-iC3b in  1.0 mS buffer with Mg  ++. 
All  B  was bound to the ATS-C3b and subsequently eluted with  10 mM EDTA 
in veronal-buffered saline.  By contrast, B was not bound to ATS-iC3b in either 
Mg  ++ or Ni ++, and eluted in the same fractions as did hemopexin. 
When B was assayed for binding to EC3b (4.5  ×  104 C3b per E) by hemolytic 
assay in  DGVB-Ni,  50%  lysis was obtained with as little as 0.5  #g/ml  of B (7.5 
molecules B/molecule  fixed  C3b).  However,  when EC3bi (5.7  ×  104  iC3b per 
E) were  substituted  for EC3b,  no B-mediated  hemolysis was detectable  with  B 
serial  dilutions  starting  at  1.0  mg/ml  (1.2  ×  104  molecules  B/molecule  fixed 
iCSb). 
Demonstration  of a  Binding  Site for  H  and  CRI  in  C3b,  iC3b,  and  C3c.  The 
binding of [~25I]-H  to  EC3b  and  EC3bi  was  examined  in  both  low  (4  mS) and 
isotonic salt buffers  (Fig.  1).  H  binding to EC3b was readily detectable  in GVB, 
whereas H  binding to EC3bi was only observed in DGVB. The calculated affinity 
of H  for EC3b  was  5  x  106 M -1  in GVB and  1.8  x  107 M -I  in DGVB,  and for ROSS  ET  AL. 
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FIGURE  l.  Binding of 12~I-labeled  factor H  to EC3b and EC3bi in isotonic versus low ionic 
strength buffer.  Different amounts of []2~I]-H  were added  to  either E,  EC3b,  or EC3bi in 
either GVB (15 mS at 22°C) or DGVB (4 mS at 22°C), and the amount of specifically bound 
[125I]-H was determined by subtraction of the nonspecific [J25I]-H binding to E from the total 
binding of [J25I]-H to EC3b or EC3bi. The specific uptake of [1251]-H in molecules per EC3b 
"  125  or EC3bi was plotted versus the initial unbound concentrauon of [  I]-H.  The EC3b were 
shown to bear 3.34 x  104 C3b molecules per cell by assay for uptake of ~25I-monoclonal anti- 
4  C3c, whereas the EC3bi were shown to bear 1.79 X  10  iC3b molecules per cell by assays for 
uptake of 12"~I-anti-C3c and 12~I-anti-C3g  (see Materials and Methods). 
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EC3bi  in  DGVB  the  affinity was  4  x  10 6  M -~.  The  calculated  number  of H 
binding sites on EC3b and EC3bi was approximately the same as the number of 
bound C3b and iC3b molecules respectively as measured by the uptake of l~sI- 
monoclonal anti-C3c. 
Because low ionic strength serum, but not isotonic serum, converted EC3bi to 
EC3d,g (6),  it  had  been  previously hypothesized that  the  H  in  low salt serum 
could serve as the  I cofactor only because the low salt permitted  H  binding to 
EC3bi.  To  confirm  this  function  of serum  H,  low  ionic  strength  serum  was 
treated with  either anti-H,  anti-CRy, a  mixture  of the two antibodies,  or PBS, 
and then examined for its ability to convert EC3bi to EC3d,g. Cleavage of EC3bi 
to EC3d,g was monitored by measuring the uptake of ]25I-monoclonal antibodies 
specific for C3c and C3g (6). As previously reported, C3c antigens were rapidly 
lost from EC3bi treated with 4 mS serum, whereas C3g antigens were retained, 
indicating conversion  to EC3d,g.  Previous addition to the 4  mS serum of anti- 
H, but not anti-CR]  or  PBS,  inhibited  C3c release by 85%,  and  a  mixture  of 
anti-H and anti-CR]  inhibited C3c release by 94%. 
The binding of iC3b and C3c to CR~  was demonstrated with iC3b- and C3c- 
coated fluorescent microspberes (Table II) and with EC3bi (Table III). H binding 
to C3c was not examined. All rosette assays with C3-ms were performed in buffer 
containing EDTA that prevented the binding of iC3b to CR3. Both iC3b-ms and 
C3c-ms were inhibited  completely from binding  to CR]-bearing cells (erythro- 
cytes, monocytes, neutrophils)  by either anti-CRy,  or fluid-phase C3b, iC3b, or 340  LOCATION  OF  DIFFERENT  BINDING  SITES  IN  C3  FRAGMENTS 
TABLE  II 
Spec~city Of Rosette Formation By Microspheres Coated With iC3b,  C3d,g and C3c 
Cell type 
C3 fragment  Rosette formation in the presence of 
011 micro- 
spheres  Buffer*  aCRl*  C3b  §  iC3b  C3c  C3d,g  C3d-OR 
Erythrocytes  iC3b  75  0  0  0  11  73  69 
C3c  72  0  0  0  14  70  72 
M  onocytes  iC3b  96  0  6  0  21  97  92 
C3d,g  91  84  86  38  88  23  31 
C3c  80  0  0  0  12  76  77 
Raji cells  iC3b  98  99  99  37  99  0  0 
C3d,g  99  99  99  51  99  3  0 
C3c  0  ND  !  ND  ND  ND  ND  ND 
* Buffer: BDVEA. 
* aCRI: F(ab').2-anti-CR~,  41  #g/4 ×  10  "~ erythrocytes or leukocytes. 
§  C3 fragment concentration: C3b, 500 ug/ml; iC3b, 400 ug/ml; C3c, 1.25  mg/ml; C3d,g, 350 ug/ 
ml. 
I ND, not done. 
C3c (Table II). With Raji cells that express CR 2 (26) and lack CR1 entirely (14, 
27,  28),  iC3b-ms binding  was  not  inhibited  by anti-CRy,  and  C3c-ms  rosettes 
were  not  observed.  The  results  obtained  with  EC3bi  were  similar  to  those 
obtained  with  iC3b-ms;  i.e.  rosette  formation  in  EDTA  buffers was inhibited 
completely by anti-CRl (Table III). CRl-dependent rosette formation with EC3bi 
required  more  C3  per  cell  than  did  EC3b  rosette  formation.  With  EC3b, 
erythrocyte  rosette  formation  (immune  adherence)  was  near  maximum  levels 
with 4 x  103 C3b per E (29, 30). However, with EC3bi, immune adherence was 
undetectable  with  1.4  x  104  iC3b per  E  in  isotonic salt buffer, and  maximum 
levels of immune adherence required  3.5 x  104 iC3b per E and low-salt buffer 
(Table III). Even though EC3bi contained 5% C3b contamination,  this C3b did 
not explain  the CR~ activity of EC3bi, as treatment  of CRvpositive EC3bi with 
10 •g/ml  of trypsin formed EC3d that still contained 3-5% contaminating  C3b 
(Table I), but totally abolished binding to CRl-bearing cells (E, monocytes, and 
neutrophils).  When  EC3bi  rosette  formation  was  assayed  with  phagocytes  in 
buffers containing calcium and magnesium,  EC3bi bound to both CR~ and CRs, 
so that  little  inhibition  of rosette formation  was produced by anti-CR~  (Table 
III). By contrast,  anti-CR~  produced complete inhibition  of human  erythrocyte 
rosettes with EC3bi in calcium-magnesium buffer (BDVA), indicating that EC3bi 
did not bind to erythrocyte CRs. With EC3bi bearing small amounts of iC3b (< 
1.4  ×  104  iC3b  per  E),  rosette  formation  with  monocytes and  neutrophils  in 
isotonic  HBSS/BSA was primarily  CRy-dependent and  selectively inhibited  by 
anti-Mac- 1 (Table I I I). As reported by Beller et al. (21), anti-Mac- 1 had no effect 
on CR1  activity measured either with  EC3b (data not shown) or with  EC3bi in 
EDTA (Table III). 
Location of the CR2-Bindi,g Site in the d Region of iC3b, C3d,g, a~d C3d.  Previous 
studies  of CRz had  demonstrated  a  specificity for both  iC3b and  C3d,  and  a ROSS ET  AL.  341 
TABLE III 
Differences in the C Receptor Specificity of EC3bi Rosette Formation Dependent Upon Divalent 
Cations, Ionic Strength, and Amount of iC3b 
EC3bi Rosette Formation 
C3bi tools  HBSS/  EDTA/  BDVEA 
Cell type  Antibody treat-  per EC3bi  BSA (Ca,  HBSS/  BDVA  (Ca,  (EDTA 6 
ment  (x 103)  Mg, 14  BSA (14  Mg, 4 mS)  mS) 
mS)  mS) 
Erythrocytes 
Monocytes 
Neutrophils 
--  14  0  0  21  10 
--  37  15  5  39  22 
--  65  22  8  60  32 
Anti-CR~  65  0  0  0  0 
--  7.9  59  0  86  0 
--  14  86  8  95  18 
Anti-CR~  14  74  0  95  0 
Mac-1  14  5  6  20  13 
--  37  97  43  95  82 
--  65  96  77  97  85 
Anti-CRi  65  85  0  94  0 
Mac-1  65  75  74  92  81 
--  14  96  2  100  11 
Anti-CR1  14  79  0  100  0 
Mac-1  14  4  3  13  9 
--  37  99  78  100  84 
--  65  99  97  100  88 
Anti-CR1  65  92  0  100  0 
Mac-I  65  95  93  100  86 
complete absence of reactivity with C3b (13, 14, 26). Because earlier preparations 
of EC3bi and EC3d probably contained variable amounts ofC3d,g, a C3 fragment 
that  was  previously  unrecognized,  fluorescent  microspheres  were  coated  with 
iC3b and C3d,g that were shown to be pure by SDS-PAGE, and then examined 
for binding to different cell types (Table II). In addition, the specificity of rosette 
formation with EC3bi (Table III) and EC3d,g (Table IV) was characterized. 
Both iC3b-ms and C3d,g-ms rosettes with CR2-bearing Raji cells were inhibited 
by fluid-phase iC3b, C3d,g, and C3d-OR (Table II). Similar results were obtained 
with EC3bi and EC3d,g (data not shown). Furthermore, C3d-ms binding to Raji 
cells was blocked by fluid phase iC3b and C3d,g (data not shown). 
Monocytes and  neutrophils  that  had  been  thought  to  lack  CR~  because  of 
absence of rosetting ability with EC3d and C3d-ms (13), bound C3d,g-ms (Table 
II) and  EC3d,g containing more than  5  x  104  C3d,g per E  (Table IV).  C3d,g- 
ms rosettes with phagocytic cells were not inhibited significantly by EDTA and/ 
or anti-CR,  (Table  II),  indicating  that  binding  was  probably not  due  to  small 
amounts of contaminating C3b or iC3b binding to CR~  and CRs. Both C3d,g-ms 
and EC3d,g rosettes with phagocytes were inhibited by C3d-OR (Tables II and 
IV), suggesting the presence of a  phagocyte CRz-like C3d receptor.  However, 
because the EC3d,g was known to contain small amounts of contaminating C3b 342  LOCATION  OF  DIFFERENT  BINDING  SITES  IN  C3  FRAGMENTS 
TABLE  IV 
Spec~citl' of EC3d,g Rosette Formation 
Cell type 
EC3d,g* Rosette Formation in the presence of 
Buffer*  Anti-CR~  C3d-OR  Anti-CRl + 
C3d-OR 
Erythroyctes  0  ND  ~  ND  ND 
Monocytes  87  74  12  3 
Neutrophils  95  76  48  21 
Raji cells  99  99  46  48 
* EC3d,g: 6.9 x  104 molecules of C3d,g per E, with C3b/iC3b contamination of 
1.5 x  103 molecules per E determined by uptake of J2~I-anti-C3c. 
* Buffer: BDVA. 
ND, not done. 
and iC3b, and because the C3d-OR contained 5% C3b-OR, a potent inhibitor of 
CR1 (20), inhibition studies with anti-CR1 were performed to determine if EC3d,g 
bound to CR1  (Table IV). Amounts of anti-CR~  sufficient to inhibit completely 
EC3b rosette formation, did produce ,~ 18% inhibition of monocyte and neutro- 
phil rosette formation with  EC3d,g.  Even though this was much less  than the 
72% inhibition (average) produced by C3d-OR, a mixture of anti-CR1 and C3d- 
OR consistently produced more inhibition than did C3d-OR alone, suggesting 
that some phagocyte rosettes with EC3d,g were due to contaminating C3b or 
iC3b binding to CR1.  Since the EC3d from which the C3d-OR were prepared 
contained virtually no iC3b detectable with 125I-anti-C3g, it appears unlikely that 
the C3d-OR  contained iC3b-OR  that  inhibited EC3d,g from binding to CR3. 
Furthermore, despite the finding that  monocyte and  neutrophii rosettes with 
EC3d,g were not observed in the presence of EDTA (data not shown), C3d,g- 
ms did bind to monocytes (Table II) and neutrophils (not shown) in the presence 
of EDTA and anti-CRl. 
The observation that monocytes and neutrophils expressed C3d-specific recep- 
tors that bound EC3d,g and C3d,g-ms, but not EC3d or C3d-ms (13), suggested 
the possibility that phagocytic cells might express low numbers of CR2, and that 
these  CR2 were detectable only with EC3d,g and C3d,g-ms because C3d,g had a 
higher affinity for CR2  than did C3d.  Comparison of EC3d,g and EC3d  CR2- 
dependent rosette formation with  Raji cells supported this hypothesis (Fig.  2). 
Raji cells bound EC3d,g that contained as few as 700 molecules of C3d,g per E, 
and nearly all cells were rosetted with EC3d,g bearing 2,200 C3d,g per cell. By 
contrast, Raji cells did not form rosettes with EC3d containing 900 C3d per E, 
and maximum rosette formation required "~5,000 C3d per E. 
Because CR2 had a higher affinity for C3d,g than for C3d, EC3d,g were coated 
with saturating amounts of monoclonal anti-C3g to determine if this blocked the 
CR2-binding site. The observation that this treatment of EC3d,g (700 C3d,g per 
E) did not inhibit Raji cell rosettes, probably indicates that the g region does not 
form part of the CR2-binding site. 
Demonstratio~  of a Common Binding Site for CR3 and K  in  iC3b.  Because iC3b 
bound to both CR~  and CR3 (Table III), the characteristics of CR~ binding to 
iC3b could only be examined with granulocytes on which the CR~ was blocked ROSS  ET  AL.  343 
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FIGURE 2.  Raji  cell  rosette  formation with  EC3d,g  and  EC3d  prepared  with  different 
amounts of C3. Different EC3bT were prepared with 1 ×  10 ~ E and varying amounts of C3 
(0.5 nag to 3.0 rag), 1~  trypsin  (wt/wt),  and incubation for 1 min at 37°C.  Each different 
EC3bT was divided into two parts that were converted into either EC3d,g or EC3d and then 
analyzed  for  uptake of ~25I-labeled monoclonal anti-C3c,  anti-C3g,  and anti-C3d.  Rosette 
formation was carried out in BDVEA buffer by incubation for  15 min at 37°C on a tube 
rotator (see Materials and Methods). 
TABLE  V 
Requirements for Divalent  Cations and Carbohydrate in the Binding of EC3bi 
to CRs and Bovine Conglutinin 
EC3bi ro- 
Molecules of iC3b/  settes with  EC3bi conglu- 
EC3bi  anti-CR1-  tination titre 
treated mon-  (K)* 
ocytes (CRy) 
BDVA 
+ 3 mM NADG 
+25 mM NADG 
BDVA 
+ 3 mM NADG 
+ 25 mM NADG 
HBSS/BSA* 
+ 20 mM EDTA 
+ 2 mM Mg-EGTA 
+ 2 mM CaCI~ 
+ 2 mM MgCI2 and 
2 mM CaC12 
7.9 ×  10  3 
1.4 ×  10  4 
1.4 x  104 
% 
44  128 
36  0 
2  0 
84  6,400 
85  0 
57  0 
0  0 
28  0 
71  6,400 
96  3,200 
* One preparation of purified K,  100 ~g/ml, was titrated under the different 
conditions listed. 
* HBSS/BSA:  Calcium and magnesium-free HBSS with I% BSA. 
with saturating amounts of anti-CRl. CR3 resembled K  in that CR3 bound only 
to iC3b and did not bind to C3b, C3c (13,  31), C3d,g (Table IV and reference 
31) or C3d (13, 31). In addition, both CR3 and K binding to EC3bi was inhibited 
completely by EDTA  (Table III and reference 32). Because K  binding to EC3bi 
was  known  to  require  both  calcium  cations  and  carbohydrate  (32),  CR~  was 
compared to K for these two characteristics (Table V). Among the several sugars 344  LOCATION  OF  DIFFERENT  BINDING  SITES  IN  C3  FRAGMENTS 
known to inhibit K activity, N-acetyl-D-glucosamine (NADG) had been shown to 
be inhibitory at  the lowest concentration,  3  mM (33).  With  EC3bi  containing 
amounts of iC3b  (7.9  ×  103  molecules per  E)  that  were suboptimal  for CRy- 
dependent  rosette  formation  and  K  activity,  3  mM  NADG  produced  little 
inhibition  of rosette  formation,  but  completely inhibited  K  activity.  Higher 
amounts of NADG did produce significant inhibition of CR~ activity in a dose- 
dependent manner, with  nearly complete inhibition  of CR3  obtained with  25 
mM NADG.  However, with EC3bi containing greater amounts of iC3b (1.4  × 
104 molecules per E),  25  mM NADG consistently produced an average of only 
32~ inhibition of CR3 activity, while completely blocking conglutination. 
To examine CR~ and K cation requirements, EC3bi and monocytes in EDTA/ 
HBSS/BSA  were  washed  into  HBSS/BSA  containing either  magnesium and 
EGTA  (to  chelate  calcium),  calcium  only,  or  a  mixture  of magnesium  and 
calcium, and then examined for CR~ and K activity (Table V).  Although both 
CR:~ and K activity were restored with calcium, CR~ differed from K in that a 
low level of CR3 activity was detectable in magnesium-EGTA, and calcium and 
magnesimn  produced  much  greater  CR3  activity  than  did  calcium  alone.  In 
another type of test, CR3 also resembled K in that both CR3-dependent neutrophil 
EC3bi  rosettes and clumps of conglutinated EC3bi were disrupted by addition 
of EDTA followed by mild agitation. 
Discussion 
The major conclusion of the present study was that C3  contained at least 4 
distinct binding sites for 6 of 11  known C3-1igands.  One binding site for factor 
B was present in C3b, but was destroyed completely by factor I cleavage of C3b 
into iC3b.  A  second binding site for factor H  and CR1  was expressed in  the c 
region of C3b, and was still detectable, although with reduced affinity, in iC3b 
and C3c. A third binding site for CRe was located in the d region of C3 and was 
exposed only after I  cleavage of C3b into iC3b or C3d,g.  The data suggested 
that the very anionic g  portion of C3d,g might enhance the charge-dependent 
binding affinity of CR2 for C3d. The fourth binding site included a carbohydrate 
moiety of C3 that was exposed only in the iC3b fragment and bound both CR3 
and conglutinin (K). 
C3  has a  central role in both  the classical  and alternative pathways, and has 
more  functions  than  any  other  single  C  component.  Each  function  of C3  is 
dependent upon  the expression  within  the molecule of a  variety of different 
binding sites, as no enzymatic activity has ever been found in the molecule. After 
C3  activation,  the labile binding site is  generated in  C3b  by disruption  of an 
internal thiolester bond in the d  region (34), and this results in a proportion of 
the C3b molecules becoming bound covalently to nearby carbohydrate or protein 
surfaces. The C3a and C3b fragments and the products of C3b degradation by 
I  (iC3b,  C3c,  and  C3d,g)  and  trypsin  (C3d)  express  binding  sites  for eleven 
different ligands:  C3a  receptor,  B,  properdin,  H,  C5,  I,  CRy,  CR2,  CR3,  C4- 
binding protein,  and  K.  Many previous  studies that  used different techniques 
have demonstrated distinct binding sites for several pairs of these ligands.  For 
example, the concurrent binding to C3b of both Bb and properdin (35), or of H 
and I (36), or of H  and properdin (36), indicated that each member of the pair ROSS ET  AL.  345 
must have a distinct binding site. More recently, the finding of monoclonal anti- 
C3 antibodies that would selectively inhibit either the B, H, or properdin binding 
sites, indicated separate binding sites for each of these ligands (37, 38). 
The loss of hemolytic activity following H and I cleavage of C3b into iC3b has 
been assumed to indicate that  I destroyed the B-binding site in C3b.  However, 
it remained  possible that a  low affinity and/or hemolytically inactive B-binding 
site might be present  in iC3b.  To investigate a  possible B-binding site in iC3b, 
both low ionic strength and nickel cations, each of which are known to enhance 
the  binding  of B  to C3b (23,  25),  were used with  either  ATS-iC3b or EC3bi. 
Because  no  binding  of B  to  iC3b  was  detected,  the  B-binding  site  in  C3b  is 
probably destroyed totally by the initial two cleavages with I. 
Previous reports of H  and  CR1  binding  to C3b suggested either  a  common 
binding  site or partially  overlapping  sites.  The  binding of both  H  and  CR~  to 
C3b is enhanced by low salt buffer (18, 23, 39), and both ligands accelerate the 
dissociation of Bb from C3b,Bb,P and serve as cofactors for I cleavage of C3b 
and iC3b (6, 8,  10).  In addition,  high concentrations of H  competitively inhibit 
CR1  binding to EC3b (40).  Even though  H  binding to EC3bi was not detected 
by past  investigators  (21),  the  finding  that  H  could serve as an  I  cofactor for 
iC3b cleavage into  C3c and  C3d,g in  low salt buffer (6),  suggested that  a  low 
affinity  H-binding  site  might  be  present  in  iC3b.  Indeed,  [125I]-H binding  to 
EC3bi was detectable only in 4  mS DGVB and not in  15 mS GVB (Fig.  1). As 
reported by Kazatchkine et al. (23), the H-binding affinity for EC3b was enhanced 
by low-salt buffer from 5  x  106 M -~  in GVB to  1.8 ×  107 M -~  in  DGVB. The 
H-binding affinity for EC3bi in DGVB (4 x  10  6 M -1) was only slightly less than 
the H  affinity for EC3b in  isotonic buffer. The numbers of H-binding sites on 
EC3b and EC3bi were approximately the same as the numbers of C3b and iC3b 
molecules  per  cell  respectively  measured  with  125I-monoclonal  anti-C3.  This 
indicated that nearly all iC3b molecules bound H  in low salt buffer, and that H- 
binding to EC3bi was not due to the small amount (<5%) of contaminating C3b 
on EC3bi. 
The observed binding of H  to EC3bi in  low salt buffer appeared to confirm 
the mechanism by which low ionic strength permitted either purified H or serum 
H  to be an  I-cofactor for cleavage of fixed iC3b (6).  However, because serum 
might contain very low amounts of free CRy, and because the binding of CRI to 
EC3bi was also increased in low salt buffer (Table III), the possibility existed that 
undetected CR~  in  low ionic strength  serum  might be the factor I-cofactor for 
iC3b cleavage. Tests of low ionic strength serum however, demonstrated that H 
and not CR~  was the primary  I-cofactor for cleavage of fixed iC3b. Treatment 
of 4 mS serum with anti-H, but not anti-CRl,  inhibited C3c release from EC3bi 
by 85%. The possibility remains that a low concentration of free CR~ in isotonic 
serum might serve as an I cofactor for the iC3b cleavage that has been observed 
in serum after C3 activation with cobra factor and incubation for 6-24 h at 37 °C 
(17). 
All previous reports have failed to demonstrate EC3bi binding to CR~ (13, 18, 
21,41). The data presented in Tables II and III show the two major reasons for 
this.  First,  fixed iC3b can  bind  to all  three  types of C3  receptors.  Second,  the 
binding of EC3bi to human  E is weak and requires both large amounts of fixed 346  LOCATION  OF  DIFFERENT  BINDING  SITES  IN  C3  FRAGMENTS 
iC3b and low ionic strength. With phagocytic cells, EC3bi binds to both CRa and 
CRy, so that neither anti-CR~ nor fluid-phase C3b produces much inhibition of 
EC3bi rosette formation (Table III and references 13, 41). Similarly, lymphocytes 
bind iC3b-ms and EC3bi to both CR~ and CR2 (Table II and reference 13). The 
binding of iC3b-ms and  EC3bi  to  monocyte and neutrophil CR1  was demon- 
strated by anti-CRl  inhibition of rosettes in EDTA buffers that prevented iC3b 
binding to CR~ (Table II and III). Anti-CR1 also blocked EC3bi rosettes com- 
pletely with human E that lacked CR3 detectable by EC3bi rosette formation. 
EC3bi bearing small amounts of iC3b bound primarily to CRs and not to CRy. 
When  these  EC3bi  were  tested  in  isotonic  buffers  containing  calcium  and 
magnesium, monocyte and neutrophil rosette formation was unaffected by anti- 
CR~  but almost completely inhibited by anti-Mac-1  (Table  III,  reference 21). 
With greater amounts of fixed iC3b,  the EC3bi  bound to both CRl  and CR3, 
and neither anti-CR~ nor anti-Mac-1 produced significant inhibition of rosettes. 
An important recent finding provided additional confirmation of both the ability 
of phagocyte CR~ to bind EC3bi and the identity of CR~ with Mac-1. Two sibling 
patients were discovered who had an apparent genetic deficiency of the leukocyte 
Mac-1  antigen. Monocytes and neutrophils from these patients formed normal 
percentages of EC3bi  rosettes  in  calcium-magnesium buffer, but these  EC3bi 
rosettes  were  inhibited  completely by  F(ab')2  anti-CR~  (Ross,  G.  D.,  R.  A. 
Thompson,  M. J.  Walport,  R.  H.  R.  Ward, J.  Lida,  R.  A.  Harrison, and P. J. 
Lachmann, manuscript in preparation). 
iC3b had a much lower affinity for CR~ than did either C3b or C4b. Maximum 
levels of immune adherence in low ionic strength buffer required "~9 times more 
iC3b than C3b (3.5 ×  10 4 iC3b per EC3bi vs. 4.0 ×  103 C3b per EC3b) and "-3 
times more iC3b than C4b (9.0 x  103 C4b per EAC14b) (29, 30). Because EC3bi 
contained "~5% contaminating C3b, it appeared possible that EC3bi binding to 
CRj  might be due entirely to  this contaminating C3b.  However, this was dis- 
counted because treatment of EC3bi with  10 ~g/ml trypsin, that cleaved fixed 
iC3b to C3d but did not cleave contaminating C3b (Table I) (42),  completely 
abolished detectable CRy-dependent rosetting of the resulting EC3d.  CRl-de- 
pendent  rosetting  with  C3b  (18,  20),  C4b  (18),  and  iC3b  (Table  III)  was 
considerably enhanced by low salt buffers, demonstrating that the CRy-binding 
site was partially charge dependent. 
The  identification of a  low affinity binding  site(s)  in  iC3b  for  CR1  and  H 
supported previous findings that the CRl-binding site was detectable in C3c (13, 
30).  In  the  present  study,  highly  purified  C3c  was  coupled  to  fluorescent 
microspheres,  and  the  resulting  C3c-ms  were  shown  to  bind  only  to  CRy. 
Attempts to use C3c-ms to investigate [1251]-H binding to C3c were not successful, 
as  a  density of oil  could  not  be  found  that  would allow  rapid  separation  by 
centrifugation of the C3c-ms from an aqueous phase containing unbound [125I]- 
H. 
The binding site for CR2  had been previously shown to be present in both 
iC3b and C3d, but not in C3b (4,  13). The C3d,g fragment, that is probably the 
normal bound end product of C3 degradation (6,  17),  had not been previously 
examined for binding to C receptors or other C3 ligands. Both C3d,g-ms (Table 
II) and EC3d,g (Table IV) bound to CR2, as rosetting was inhibited by C3d-OR. ROSS  ET  AL.  347 
However, a comparison of EC3d,g and EC3d indicated that CR2  had a  higher 
affinity for C3d,g  than  for C3d  (Fig.  2).  Although  fluid-phase C3d  inhibited 
EC3d  rosette formation (13),  more than  1.0  mg/ml  of C3d  was  required  to 
inhibit EC3d,g rosette formation (data not shown). Because of this finding and 
the demonstration of C3d,g-ms (Table  II) and  EC3d,g (Table  III) binding to 
phagocytic cells,  it  was at  first  believed  that  C3d,g  bound  to  CR3  (43,  44). 
Subsequently however, C3d-OR complexes were found to block C3d,g-ms and 
EC3d,g rosette formation with all cell types, and anti-Mac-1 (anti-CR3) was found 
to  have  no  effect  on  EC3d,g  rosette  formation  (data  not  shown).  C3d-OR 
resembled C3b-OR  (20) in  having a  much greater ability to block C receptors 
than did uncomplexed C3d or C3b. The most potent inhibitor of CR~ was C3d,g- 
OR. The CR2 on Raji cells were completely blocked by treatment with microgram 
amounts of C3d,g-OR, and Raji cells were still  unable to form EC3d,g or EC3d 
rosettes after three washing steps (Ross, G., unpublished observation). Because 
EC3d,g had a  higher affinity for CR~ than did EC3d, the g portion of EC3d,g 
was saturated  with  monoclonal anti-C3g  to  determine if this  might block  the 
CR2-binding site.  Because the attachment of an  intact  IgG  molecule to  the g 
region (8,000  daltons) caused no detectable inhibition of Raji  cell rosette for- 
mation, it appears  unlikely that C3g forms a  part of the CRz-binding site.  An 
alternative explanation for the higher affinity of CR~ for C3d,g as compared to 
C3d may be the much greater electrophoretic charge of C3d,g (17). As with CR1 
and CRy, the rosetting activity of CRy-bearing ceils was greatly enhanced in low 
ionic strength buffer (26), indicating that charge interactions were very important 
for the CRy-binding site. Perhaps the charge contributed by the anionic g region 
of C3d,g enhances the attraction of CR2 for the d region of C3d,g. 
The  enhanced  CR~  binding  of C3d,g  as  compared  to  C3d  probably  also 
explains  the  observed  rosette  formation  of monocytes and  neutrophils  with 
C3d,g-ms and EC3d,g (Table II and IV). Because phagocytes did not bind C3d- 
ms (13) or EC3d (13, 21), nor stain with anti-CR2 (26), these cells were previously 
believed to lack CR2.  EC3d,g binding to phagocytic cells required >5.0  ×  10 4 
C3d,g molecules per EC3d,g, and was greatly enhanced by low ionic strength 
buffer. Because EC3d,g contained  ,~5%  C3b and iC3b  detectable with [~sI]- 
anti-C3c  (Table  I),  the  involvement of this  contaminating  C3b  and  iC3b  in 
EC3d,g rosette formation was investigated. Anti-CR~ did produce 18% inhibition 
of monocyte-EC3d,g rosettes, but C3d-OR produced an average of 72% inhibi- 
tion. In addition, C3d,g-ms binding to phagocytes was inhibited by C3d-OR but 
not by anti-CR~ in EDTA buffers, indicating that C3d,g-ms did not bind to CRI 
or CR3 (Table II). Thus, the data suggest that phagocytic cells may express very 
small amounts of CR2.  In the future, tests for anti-CR2 inhibition of phagocyte 
EC3d,g rosettes will be required to confirm this conclusion. 
Because iC3b binds to all three types of C3 receptors, it has been particularly 
difficult to define the cell type distribution of CR3. For example, iC3b-dependent 
rosette formation with anti-CR2- or C3d-treated B lymphocytes was thought to 
detect B  lymphocyte CR3  (13).  With recognition both that  B lymphocyte CR~ 
could bind to fixed iC3b and that B cells lacked the Mac-1  antigen (19), it now 
appears likely that B cells lack CR3 and express only CR1 and CR2.  On the other 
hand, the cytotoxic activity of antibody-dependent killer cells, that express the 348  LOCATION  OF  DIFFERENT  BINDING  SITES  IN  C3  FRAGMENTS 
Mac-1  antigen (19) and lack CR1 (28), has been shown to be enhanced by target 
cell-bound iC3b (45), probably indicating that this other type of lymphoid cell 
does indeed express CRy. 
A particularly interesting finding was that CR3 had a conglutininlike binding 
activity for fixed iC3b. Previous studies of EC3bi binding to phagocytic cells did 
not detect any significant inhibition by EDTA or NADG, as EC3bi were bound 
to CR1  whenever CR3 were inhibited. Characterization of the CR3-binding site 
thus  required  prior  blockade  of neutrophil  or  monocyte CRl  with  anti-CRy. 
Comparison of CR3 and K revealed that both ligands required calcium and were 
inhibited by NADG (Table V).  However, CR3 differed from K in that a  small 
amount of CR3  activity was detected in  magnesium/EGTA, and a  mixture of 
calcium  and  magnesium  produced  significantly  more  CR3  activity  than  did 
calcium alone. In addition, CR~ activity was less sensitive to NADG than was K 
activity (Table V). Thus, while both CR3 and K may bind to the same carbohy- 
drate in  iC3b,  the CR3  requirement for magnesium and greater resistance to 
NADG inhibition suggests that CR3 may bind to a second site in iC3b that does 
not bind to K. 
Additional experiments in the future will be required to confirm the identity 
of a single binding site for H and CRy. It is of interest that a C3-affinity-purified 
antibody was produced that was specific for the idiotype of anti-H antibody and 
blocked  the  uptake  of  [3H]-labeled  H  onto  both  EC3b  and  lymphocyte  H 
receptors (46).  This  same anti-anti-H  not only bound  to  EC3b  (46),  but  also 
bound to EC3bi (Lambris, J., unpublished observation), and thus was probably 
specific for the H-binding site of C3.  In the future, attempts will  be made to 
produce more of this antibody to ascertain if it blocks simultaneously both the 
H  and CR1 binding sites in C3b. The similarity of the CR3 and K binding sites 
also requires further study. K not only binds a carbohydrate in fixed iC3b, but 
also  is  known  to  bind  directly to  certain  mannan-containing extracts  derived 
from zymosan (42).  Because monocytes express mannan-specific receptors (47), 
and neutrophils are able to bind weakly to unopsonized zymosan (48), it will be 
especially important to determine if phagocyte CRs are mannan-specific and able 
to bind yeast particles to phagocytes. Finally, the similarity of CR3 and K suggests 
the possibility that bovine serum K may be a secreted form of leukocyte mem- 
brane CR3. 
Summary 
The many different recognized functions of C3 are dependent upon the ability 
of the activated C3 molecule both to bind covalently to protein and carbohydrate 
surfaces and to provide binding sites for as many as eleven different proteins. 
The location of the binding sites for six of these different proteins (factors B and 
H, complement receptors CRy, CR2 and CR.% and conglutinin) was examined in 
the  naturally  occurring C3-fragments  generated by  C3  activation  (C3b)  and 
degradation by  Factor  I  (iC3b,  C3c,  C3d,g)  and  trypsin  (C3d).  Evidence was 
obtained for at least four distinct binding sites in C3 for these six different C3 
ligands.  One binding site for B was detectable only in C3b,  whereas a  second 
binding site for H  and CR1  was detectable in both C3b and iC3b.  The affinity 
of the  binding  site  for  H  and  CR1  was  charge  dependent and  considerably ROSS ET  AL.  349 
reduced in iC3b as compared to C3b.  H  binding to iC3b-coated sheep erythro- 
cytes (EC3bi)  was  measurable  only in  low  ionic  strength  buffer (4  mS).  The 
finding that C3c-coated microspheres bound to CR1,  indicated that this second 
binding site was still intact in the C3c fragment. However, H binding to C3c was 
not examined. A third binding site in C3 for CR2 was exposed in the d  region 
by factor I cleavage of C3b into iC3b, and the activity of this site was unaffected 
by the further I cleavage of iC3b into C3d,g. Removal of the 8,000-dalton C3g 
fragment from C3d,g with trypsin forming C3d, resulted in reduced CR2 activity. 
However, because saturating amounts of monoclonal anti-C3g did not block the 
CR2-binding activity of EC3d,g, it appears unlikely that the g region of C3d,g or 
iC3b  forms a  part  of the  CR2-binding site.  In  addition, detergent-solubilized 
EC3d (C3d-OR) inhibited the CR2-binding activity of EC3d,g.  Monocytes and 
neutrophils,  that  had  been  previously thought  to  lack  CR2  because  of their 
inability to form EC3d  rosettes, did bind EC3d,g containing >5  ×  10 4 C3d,g 
molecules per E. The finding that monocyte and neutrophil rosettes with EC3d,g 
were inhibited by C3d-OR, suggested that these phagocytic cells might indeed 
express  very  low  numbers  of CR2,  and  that  these  CR2  were  detectable  with 
EC3d,g and not with EC3d because C3d,g had a higher affinity for CR2 than did 
C3d. A fourth C3 binding site for CR~ and conglutinin (K) was restricted to the 
iC3b fragment. Because of simultaneous attachment of iC3b to phagocyte CR~ 
and CR3, the characteristics of iC3b binding to CR3 could only be examined with 
phagocytes on which the CR~ had been blocked with anti-CRy. Inhibition studies 
with EDTA and N-acetyI-D-glucosamine demonstrated a  requirement for both 
calcium cations and carbohydrate in  the  binding of EC3bi  to  CR3  and  to  K. 
However,  CRs  differed from  K  in  that  magnesium cations  were  required  in 
addition to calcium for maximum CR3  binding activity, and NADG produced 
less inhibition of CR~ activity than of K activity. 
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